Shufro Rose & Co. LLC Purchases 4,553 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Shufro Rose & Co. LLC significantly increased its position in Regeneron Pharmaceuticals by 777%, acquiring an additional 4,553 shares, bringing their total holdings to 5,139 shares worth approximately $3.26 million.
• Several analysts have revised their price targets for Regeneron Pharmaceuticals, with UBS raising theirs to $584, while Bank of America lowered it to $547, reflecting mixed sentiments about the stock's performance.
• The stock currently has a moderate buy rating from analysts, with an average price target of $837.61 despite a recent earnings miss where EPS was reported at $8.22 compared to estimates of $8.83.

Shufro Rose & Co. LLC lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 777.0% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,139 shares of the biopharmaceutical company's stock after acquiring an additional 4,553 shares during the quarter. Shufro Rose & Co. LLC's holdings in Regeneron Pharmaceuticals were worth $3,260,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Adirondack Trust Co. raised its position in shares of Regeneron Pharmaceuticals by 4.2% during the first quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock worth $286,000 after acquiring an additional 18 shares during the last quarter. Kingswood Wealth Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 1.8% during the first quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock worth $681,000 after purchasing an additional 19 shares during the period. Creative Financial Designs Inc. ADV grew its stake in shares of Regeneron Pharmaceuticals by 9.5% during the first quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock worth $139,000 after purchasing an additional 19 shares during the period. Private Trust Co. NA grew its stake in shares of Regeneron Pharmaceuticals by 13.1% during the first quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock worth $104,000 after purchasing an additional 19 shares during the period. Finally, Proficio Capital Partners LLC grew its stake in shares of Regeneron Pharmaceuticals by 6.2% during the first quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock worth $207,000 after purchasing an additional 19 shares during the period. Institutional investors own 83.31% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on REGN shares. UBS Group lifted their price objective on Regeneron Pharmaceuticals from $560.00 to $584.00 and gave the stock a "neutral" rating in a research note on Friday, July 11th. Bank of America decreased their price objective on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research note on Thursday, April 17th. Wall Street Zen cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. Robert W. Baird decreased their price objective on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research note on Friday, April 25th. Finally, Wells Fargo & Company cut Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and decreased their price objective for the stock from $700.00 to $580.00 in a research note on Friday, May 30th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $837.61.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $545.46 on Friday. The firm has a market cap of $58.89 billion, a price-to-earnings ratio of 13.89, a price-to-earnings-growth ratio of 2.08 and a beta of 0.33. The stock's 50-day moving average is $538.64 and its 200-day moving average is $604.99. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business's revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter last year, the firm earned $9.55 earnings per share. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.